Live Breaking News & Updates on Johnson Lau|Page 10
Stay updated with breaking news from Johnson lau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kryptoměny v roce 2020: Růst kurzu Bitcoinu, ale i jeho technologický vývoj a snahy o regulaci lupa.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lupa.cz Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference Athenex, Inc.January 5, 2021 GMT BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39th annual J. P. Morgan Healthcare Conference. Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development, will present a corporate overview at the conference. ....
Updated Study Data Shows Oral Paclitaxel and Encequidar Is Beneficial in Patients with Metastatic Breast Cancer pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
On May 14, the company presented data from the vibegron EMPOWUR 52-week extension study and data by age groups from the 12-week placebo-controlled EMPOWUR study at the 2020 American Urological Association Annual Meeting. The data supported the potential benefits of the drug for OAB in patients with urge urinary incontinence (UUI), urgency, and urinary frequency. The drug is a once-daily, beta-3 adrenergic agonist. David Staskin, principal investigator of EMPOWUR and a urologist with St. Elizabeth’s Medical Center and associate professor of Urology at Tufts University School of Medicine, said at the time, “The results of the EMPOWUR study over the 52-week period demonstrated the sustained benefits of vibegron. Vibegron could be a potentially important and differentiated new oral treatment, if approved by the FDA, for patients suffering with OAB.” ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic . Athenex, Inc.December 15, 2020 GMT Klisyri is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launch Klisyri in the U.S. in first quarter 2021 BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scal ....